Elizabeth Phillips Archives
May. 6, 2020—According to the U.S. Centers for Disease Control and Prevention, fewer than 1% of the population is truly allergic to penicillin. The rest were never allergic to begin with or have outgrown their allergy — an estimated 80% of people with penicillin allergy lose their sensitivity to the drug within 10 years.
Oct. 17, 2019—A program in the Medical Intensive Care Unit has successfully removed penicillin allergy labels from more than 45 inpatients at high risk to receive antibiotics, but whose penicillin allergies were low risk.
Feb. 28, 2019—Researchers at Vanderbilt University Medical Center and colleagues have identified a gene that increases the risk for a severe and potentially life-threatening reaction to the commonly prescribed antibiotic vancomycin.
Sep. 27, 2018—by Bill Snyder Two years ago when she was given a type of penicillin to fight off bacterial pneumonia, Kelly Cummins developed a rash, itching and shortness of breath. Suspecting she was having a reaction to the life-saving medication, her doctor stopped the penicillin and substituted a different class of antibiotic. Cummins recovered but now...
May. 31, 2018—Thirty years ago when she was 16, Katie Niemeyer was prescribed carbamazepine for depression. Three weeks later she was in a St. Louis, Missouri, burn unit with second and third degree burns all over her body. “My parents were told the chances of me surviving were slim,” she said.
Apr. 12, 2018—Alpha-gal allergy has commonly been referred to as “the red meat” allergy, but doctors at the Vanderbilt Asthma, Sinus and Allergy Program (ASAP) helped uncover that not only red meat, but some medications, can contain alpha-gal.
Dec. 21, 2016—Last year Paul and Wanpen Anderson of Champaign, Illinois, were preparing to celebrate the Christmas holidays with their two children when their 22-year-old daughter, Angela, developed a rare adverse drug reaction called SJS/TEN.
Mar. 14, 2013—VUMC’s personalized medicine effort is getting a major boost with the recruitment of two physician-scientists from Australia who will increase Vanderbilt’s strength in translational immunology, the translation of basic immunological discoveries into clinically useful tools.